Neurocrine Biosciences has shared a letter with the Prader-Willi syndrome (PWS) community.
Earlier this year, Neurocrine Biosciences acquired Soleno Therapeutics and became the new steward of VYKAT® XR (diazoxide choline) extended-release tablets.
Kyle Gano, CEO of Neurocrine, has shared a message outlining their commitment to the PWS community and next steps for generating important real-world data, expanding the knowledge base, and further informing how Vykat XR is prescribed.
We encourage all members of the PWS community to stay informed and engaged as this work moves forward. You can help ensure that the experiences, needs, and voices of the PWS community continue to guide future research, treatment decisions, and progress for everyone with PWS.
